MANAGEMENT OF CROHNS-DISEASE - NEW THERAPEUTIC APPROACHES

被引：0

作者：

RACHMILEWITZ, D

机构：

[1] Department of Medicine, Hadassah University Hospital, Jerusalem

来源：

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY | 1994年 / 6卷 / 02期

关键词：

FREE RADICALS; PLATELET-ACTIVATING FACTOR; SOMATOSTATIN; KETOTIFEN; NITROXIDES;

D O I：

10.1097/00042737-199402000-00003

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

As long as the etiology of Crohn's disease is unknown, the development of new therapeutic modalities should take the increased understanding of the pathogenesis of the disease into consideration. Modulation of inflammatory mediators with specific lipoxygenase inhibitors or with specific platelet-activating factor receptor antagonists may be of value. Drugs such as ketotifen and synthetic somatostatin analogues, which inhibit the release of mediators from inflammatory cells, may be of benefit in view of their antisecretory and anti-inflammatory effects. The crucial role of free radicals in the pathogenesis of tissue injury advocates trial with potent scavengers, such as nitroxides, whereas there is still a place for further trials with antimycobacterial therapy.

引用

页码：108 / 112

页数：5

共 30 条

[1]

Eliakim R., Rachmilewitz D., Potential mediators in inflam-matory bowel disease, Gastroenterol Int, 5, pp. 48-56, (1992)

[2]

Stenson W.F., Laurjsten K., Laursen L.S., Rask-Madsen J., Jacobsen O., J N., Et al., A clinical trial of zileuton,a specific inhibitor of 5-lipoxygenase in ulcerative colitis [abstract], Gastroenterology, 100, (1991)

[3]

Stenson W.F., Cort D., Rodgers J., Burkoff R., Deschryver-Kecskemeti K., Gramlich T.L., Et al., Dietary supplementation with fish oil in ulcerative colitis, Ann Intern Med, 116, pp. 609-614, (1992)

[4]

Wallace J.L., Release of platelet activating factor (PAF) andaccelerated healing induced by a PAF antagonist in an animal model of chronic colitis, Can J Physiol Pharmacol, 66, pp. 422-425, (1988)

[5]

Grant S.M., Goa K.L., Fitton A S.E., Ketotifen. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in asthma and allergic disorders, Drugs, 40, pp. 412-448, (1990)

[6]

Pothoulakis C., Karmeli F., Kelly C.P., Eljakim R., Joshi M.A., O'keane J.O., Et al., Gastroenterology, 105, pp. 701-707, (1993)

[7]

Eliakim R., Karmeli F., Okon E., Rachmilewitz D., Ketotifeneffectively prevents mucosal damage in experimental colitis, Gut, 33, pp. 1498-1503, (1992)

[8]

Eliakim R., Karmeli F., Rachmilewitz D., Ketotifen-old drug, new indication-reduction of gastric mucosal injury, Scand J Gastroenterol, 28, pp. 202-209, (1993)

[9]

Beagley K.W., Elson C.O., Cells and cytokines in mucosal immunity and inflammation, Gastroenterol Clin North Am, 21, (1992)

[10]

Comminelli F., Cc N., Duchini A., Lee M., Recombinant interleukin-l receptor antagonist blocks the proinflammatory activity of endogenous interleukin-l in rabbit immune colitis, Gastroenterology, 103, pp. 65-71, (1992)

← 1 2 3 →